**Core Concept**
Beta-blockers with intrinsic sympathomimetic activity (ISA) are a class of medications that exhibit partial agonist activity at beta-adrenergic receptors, providing a balance between blocking and stimulating the receptor. This property allows them to offer some of the benefits of beta-blockade while minimizing the risk of adverse effects associated with full beta-blockade.

**Why the Correct Answer is Right**
These beta-blockers, such as pindolol and acebutolol, exert a partial agonist effect at beta-1 and beta-2 adrenergic receptors, resulting in a mild increase in heart rate, contractility, and vasodilation. This ISA property is thought to be mediated through a conformational change in the beta-adrenergic receptor, allowing the partial agonist to stabilize the receptor in a low-affinity state, thereby reducing the risk of excessive beta-blockade.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specify a beta-blocker with intrinsic sympathomimetic activity.
**Option B:** This option is incorrect because it refers to a beta-blocker with a non-selective beta-blocking profile, which does not exhibit ISA.
**Option C:** This option is incorrect because it refers to a different class of medications altogether, which does not possess beta-blocking or ISA properties.

**Clinical Pearl / High-Yield Fact**
Beta-blockers with intrinsic sympathomimetic activity are often preferred in patients with asthma or chronic obstructive pulmonary disease (COPD), as they tend to cause fewer bronchoconstrictive effects compared to non-selective beta-blockers.

**Correct Answer:** C. Pindolol.